News

Date Title View
Toggle Summary Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido , Jr., Ph.D., chairman and chief executive officer, will present in a fireside chat discussion at the RBC Capital Markets Global
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Product Candidate Features AR-13324, Aerie's Lead Compound, Combined with Latanoprost in a Single Drop Once-Daily Therapy Topline Results of Phase 2b Study Expected in Mid-2014 BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals
Results Also Suggest a Potential New Mechanism of Action Aerie Reaffirms Timeline to Commence Two Phase 3 Studies by mid-2014 BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Business and Product Development Update
Aerie Successfully Completes Initial Public Offering Proceeding with Clinical Trials for Highly Differentiated Glaucoma Products Conference Call and Webcast Today, December 4 , at 5:00 p.m. ET BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, December 4, 2013
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2013 financial results will be released after the market closes on Wednesday, December 4, 2013 .
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) announced today the closing of its initial public offering of 7,728,000 shares of its common stock, including 1,008,000 shares of common stock issued upon the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Pricing of Initial Public Offering
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. , announced today the pricing of its initial public offering of 6,720,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts.
View HTML
Toggle Summary Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering BEDMINSTER, N.J, RESEARCH TRIANGLE PARK, N.C., & NEWPORT BEACH, CA – September 17, 2013 – Aerie Pharmaceuticals, Inc., announced today that the Company has filed a registration statement on Form
View HTML
Toggle Summary Aerie Pharmaceuticals Elects Dr. Gerald D. Cagle to the Company’s Board of Directors
Aerie Pharmaceuticals Elects Dr. Gerald D. Cagle to the Company’s Board of Directors Bedminster, NJ, and Research Triangle Park, NC – September 5, 2013 – Aerie Pharmaceuticals, Inc., announced today that Gerald D. Cagle, Ph.D., has been elected to the Company’s Board of
View HTML